Oral anticoagulation in end-stage renal disease and atrial fibrillation: Is it time to just say no to drugs?

Heart

Volumn 103, Issue 11, 2017, Pages 807-808

  Black Maier, Eric ^a   Piccini, Jonathan P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DIRECT ORAL ANTICOAGULANT; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MONITORING; DRUG USE; EDITORIAL; END STAGE RENAL DISEASE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; META ANALYSIS (TOPIC); MORTALITY; PHARMACOLOGICAL PARAMETERS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOEMBOLISM; TIME IN THERAPEUTIC RANGE; BLOOD CLOTTING; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; FIBRINOLYTIC THERAPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; HUMANS; KIDNEY FAILURE, CHRONIC; STROKE; THROMBOLYTIC THERAPY;

EID: 85009776416     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-310540     Document Type: Editorial

References (11)

1. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-86.
2. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-8.
3. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33.
4. Olesen JB, Lip GYH, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35.
5. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-203.
6. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106.
7. Yang F, Hellyer J, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017;103:818-26.
8. Pokorney SD, Simon DN, Thomas L, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015;170:141-8, 48.e1.
9. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007;167:239-45.
10. Jha AK, Perlin JB, Kizer KW, et al. Effect of the transformation of the veterans affairs health care system on the quality of care. N Engl J Med 2003;348:2218-27.
11. Piccini JP, Sievert H, Patel MR. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. Eur Heart J 2016. Sep 13. pii: ehw330.s